Optimized, reduced-pill count targeted therapy for metastatic castration-resistant and castration-sensitive advanced prostate carcinoma.
Optimized, reduced-pill count targeted therapy for metastatic castration-resistant and castration-sensitive advanced prostate carcinoma.
Blocks androgen synthesis at all three anatomical sources (testes, adrenals, and the tumor itself) by inhibiting the CYP17 enzyme. This stops testosterone production, slowing tumor growth.
Severe hypokalemia, hypertension, peripheral edema, elevated transaminases, diarrhea, and urinary tract infections.
It reduces the daily pill count from four 250mg tablets to just two 500mg tablets, simplifying the patient's daily medication routine.
Yes, the 500mg tablets must be taken on an empty stomach, either 1 hour before or 2 hours after a meal.
Inform your physician immediately. Antihypertensive therapy may need to be adjusted, and the prednisone dose verified.
It is not recommended for patients with baseline severe liver failure (Child-Pugh Class C) due to an increased risk of toxicity.
Yes, muscle weakness can occur as a symptom of low potassium levels (hypokalemia) caused by mineralocorticoid excess.
Blood pressure should be measured at least once a month, or more frequently if the patient has a history of cardiovascular disease.
Yes, profound testosterone suppression frequently induces hot flashes and a reduced libido, which are common effects of hormone therapy.
Arrhythmias are typically triggered by severe hypokalemia, making strict management of potassium levels essential.
Always verify with your pharmacist, as Abiraterone is metabolized by liver enzymes and can interact with various compounds.
Store below 30?C in a dry area, well out of reach of children and pregnant women.